[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Hepion Pharms Inc (HEPA)

Hepion Pharms Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 491
  • Shares Outstanding, K 11,435
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,190 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.21
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -72.15
  • Most Recent Earnings $-2.15 on 05/19/25
  • Next Earnings Date 08/12/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0481 +66.94%
on 08/07/26
0.0950 -15.47%
on 08/28/26
+0.0344 (+74.95%)
since 07/31/26
3-Month
0.0441 +82.09%
on 07/24/26
0.0950 -15.47%
on 08/28/26
+0.0173 (+27.46%)
since 06/02/26
52-Week
0.0341 +135.48%
on 01/30/26
0.1100 -27.00%
on 05/18/26
+0.0147 (+22.41%)
since 09/02/25

Most Recent Stories

More News
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s...

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven...

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is...

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is...

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been...

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

HEPA : 0.0803 (+7.07%)
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been...

HEPA : 0.0803 (+7.07%)

Business Summary

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular...

See More

Key Turning Points

3rd Resistance Point 0.0992
2nd Resistance Point 0.0943
1st Resistance Point 0.0847
Last Price 0.0803
1st Support Level 0.0702
2nd Support Level 0.0653
3rd Support Level 0.0557

See More

52-Week High 0.1100
Fibonacci 61.8% 0.0810
Last Price 0.0803
Fibonacci 50% 0.0720
Fibonacci 38.2% 0.0631
52-Week Low 0.0341

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.